levofloxacin has been researched along with lansoprazole in 27 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (lansoprazole) | Trials (lansoprazole) | Recent Studies (post-2010) (lansoprazole) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 2,281 | 803 | 600 |
| Protein | Taxonomy | levofloxacin (IC50) | lansoprazole (IC50) |
|---|---|---|---|
| phosphoethanolamine/phosphocholine phosphatase isoform 1 | Homo sapiens (human) | 0.434 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.995 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.3148 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.3367 | |
| WD repeat-containing protein 5 | Homo sapiens (human) | 5.9 | |
| Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 5.9 | |
| Indoleamine 2,3-dioxygenase 2 | Mus musculus (house mouse) | 8.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (37.04) | 29.6817 |
| 2010's | 17 (62.96) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Asaumi, N; Kiguchi, T; Masuda, K; Niiya, K; Niiya, M; Tanimoto, M; Yoshida, C | 1 |
| Aoyama, N; Fukuda, M; Kachi, M; Kasuga, M; Kuroda, K; Maekawa, S; Miki, I; Shirasaka, D; Tamura, T; Wambura, C; Watanabe, Y | 1 |
| Chan, AO; Chan, CK; Chu, KM; Fung, FM; Gu, Q; Lai, KC; Tong, TS; Wong, BC; Wong, WM; Yee, YK | 1 |
| Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Wu, JJ; Yang, HB | 1 |
| Barbuti, RC; Eisig, JN; Malfertheiner, P; Moraes Filho, JP; Rodriguez, TN; Silva, FM; Zaterka, S | 1 |
| Angelini, R; Pontone, P; Pontone, S; Standoli, M | 1 |
| Bağci, S; Erçin, CN; Kantarcioğlu, M; Kilciler, G; Polat, Z; Toros, AB; Uygun, A | 1 |
| Akkan Çetinkaya, Z; Düzgün, S; Erhan Altunöz, M; Günes, P; Güzelbulut, F; Ovünç Kurdas, O; Sezikli, M | 1 |
| Higuchi, W; Imamura, Y; Kanda, H; Nishiyama, A; Takano, T; Taneike, I; Yamamoto, T; Yoshida, K | 1 |
| Basu, PP; Flynn, M; Krishnaswamy, N; Pacana, T; Rayapudi, K; Shah, NJ | 1 |
| Amagai, K; Ando, T; Asaka, M; Furuta, T; Hori, S; Inaba, T; Inoue, S; Inui, Y; Iwamoto, J; Kamoshida, T; Kato, M; Kodama, M; Kudo, M; Mabe, K; Miwa, J; Mizuno, S; Murakami, K; Nakajima, T; Nomura, H; Ohkusa, T; Okimoto, T; Oshima, T; Sasaki, M; Satoh, K; Suganuma, T; Take, S; Tomita, T; Tomokane, T; Yamamoto, S | 1 |
| Imai, Y; Inokuma, T; Matsumoto, T | 1 |
| Akdogan, RA; Ayaz, T; Bedir, R; Rakici, H | 1 |
| Cao, Z; Chen, Q; Liang, X; Liao, J; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Barbuti, RC; Eisig, JN; Iriya, K; Lee, JH; Mattar, R; Navarro-Rodriguez, T; Queiroz, EC; Silva, FM | 1 |
| Argentieri, A; Caroleo, MC; Cione, E; Codamo, G; De Sarro, G; Gallelli, G; Gallelli, L; Longo, P; Michniewicz, A; Siniscalchi, A; Stefanelli, R | 1 |
| Bair, MJ; Chang, CC; Chang, CY; Chang, WH; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Fang, YJ; Hsu, WF; Hung, HW; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tseng, CH; Wu, JY; Wu, MS; Yang, TH | 1 |
| Shahbazi, S; Vahdat Shariatpanahi, Z | 1 |
1 review(s) available for levofloxacin and lansoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 trial(s) available for levofloxacin and lansoprazole
| Article | Year |
|---|---|
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 2006 |
Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Constipation; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Nausea; Ofloxacin; Treatment Outcome; Vomiting | 2007 |
Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Salvage Therapy; Treatment Outcome | 2009 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Treatment Outcome | 2010 |
Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Ofloxacin | 2010 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Levofloxacin; Male; Middle Aged; Nitro Compounds; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Recurrence; Thiazoles; Young Adult | 2011 |
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Drug Resistance; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Levofloxacin; Male; Middle Aged; Treatment Outcome | 2013 |
Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Stomach Diseases; Treatment Outcome | 2016 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Patient Compliance; Tinidazole; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
15 other study(ies) available for levofloxacin and lansoprazole
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Helicobacter pylori eradication based upon a drug sensitivity test effectively increased platelet count in a patient with refractory idiopathic thrombocytopenic purpura].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Ofloxacin; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Failure | 2003 |
Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Ofloxacin; Prospective Studies; Treatment Outcome | 2011 |
Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Drug Combinations; Fluoroquinolones; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin | 2011 |
Education and imaging. Gastrointestinal: colonic mucosa-associated lymphoid tissue lymphoma regressed by levofloxacin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colonic Neoplasms; Colonoscopy; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Endosonography; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lansoprazole; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Multimodal Imaging; Occult Blood; Ofloxacin; Polymerase Chain Reaction; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Brazil; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Young Adult | 2015 |
Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company.
Topics: Adult; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged | 2016 |